rs1927911 — TLR4

TLR4 and the Immune Root of Atherosclerosis

Atherosclerosis has long been recognized as more than a simple plumbing problem — it is fundamentally an inflammatory disease. At its center sits Toll-Like Receptor 4 (TLR4)¹¹ Toll-Like Receptor 4 (TLR4)
a pattern recognition receptor on the surface of immune cells and vascular endothelium that detects lipopolysaccharide (LPS) from Gram-negative bacteria and endogenous danger signals such as oxidized LDL. When TLR4 fires, it triggers NF-κB signaling and a cascade of pro-inflammatory cytokines — TNF-α, IL-6, IL-1β — that drive plaque formation and destabilization. rs1927911 is an intronic variant in TLR4 that acts as a tag SNP for haplotype variation across the gene, with the A allele (reported as T in chip notation) associated with modestly attenuated TLR4-driven vascular inflammation.

The Mechanism

TLR4 sits on chromosome 9q32-q33 and is expressed on monocytes, macrophages, dendritic cells, vascular endothelial cells, and smooth muscle cells. Upon detecting LPS or endogenous ligands (heat shock proteins, oxidized phospholipids, fibronectin), TLR4 dimerizes, recruits MyD88 and TRIF adaptor proteins²² MyD88 and TRIF adaptor proteins
intracellular signaling scaffolds that relay TLR4 activation to downstream kinase cascades, and activates NF-κB. The result: transcription of pro-inflammatory genes in the arterial wall that promote foam cell formation, smooth muscle proliferation, and plaque instability. rs1927911 lies in intron 1 and is thought to tag regulatory variation that modulates TLR4 expression or splicing in vascular tissues, rather than altering the receptor's LPS-binding domain directly. Carriers of two G alleles may have somewhat higher TLR4-mediated inflammatory tone in the vessel wall.

The Evidence

The cardiovascular link was established through several lines of evidence:

Enquobahrie et al. 2008³³ Enquobahrie et al. 2008
Cholesterol Ester Transfer Protein, Interleukin-8, PPARA, and Toll-like Receptor 4 Genetic Variations and Risk of Incident Nonfatal Myocardial Infarction and Ischemic Stroke. Am J Cardiol, 2008 studied 848 MI cases and 2,682 controls drawn from postmenopausal women and hypertensive men and women. They found the rs1927911 A allele (reported as T in chip notation) associated with a lower risk of nonfatal MI (OR 0.88, 95% CI 0.77–0.99), consistent with reduced TLR4-mediated vascular inflammation.

A 2017 systematic review and meta-analysis⁴⁴ 2017 systematic review and meta-analysis
Xie et al. Roles of TLR Gene Polymorphisms in Atherosclerosis. Scand J Immunol of 35,317 subjects across 40 studies found that TLR4 rs1927911 was significantly associated with cerebral infarction in the recessive model (OR 0.67, 95% CI 0.46–0.96, P=0.03), suggesting AA homozygotes have meaningfully lower cerebral infarction risk compared to GG+AG individuals.

An earlier Song et al. 2015⁵⁵ Song et al. 2015
TLR4 rs1927911, but Not TLR2 rs5743708, Is Associated With Atherosclerotic Cerebral Infarction in the Southern Han Population. Medicine 94:e381 case-control study (170 ACI patients, 149 controls) found genotype and allele frequencies significantly differed between ACI patients and healthy controls, nominating rs1927911 as a risk factor for atherosclerotic cerebral infarction. Critically, this effect was independent of blood pressure, fasting blood glucose, and serum lipids — pointing to an inflammatory mechanism rather than metabolic mediation.

Mechanistic support comes from the landmark Kiechl et al. 2002 NEJM⁶⁶ Kiechl et al. 2002 NEJM
Toll-Like Receptor 4 Polymorphisms and Atherogenesis study establishing that TLR4 signaling attenuation (via the coding Asp299Gly variant) reduces carotid atherosclerosis progression, validating the TLR4 pathway as genuinely causal in human atherogenesis rather than merely correlative.

Evidence is moderate — population studies are replication-level but effect sizes are modest (OR ~0.88 for MI), and the intronic rs1927911 does not have a confirmed functional mechanism of its own; it acts as a proxy for TLR4 haplotype variation.

Practical Actions

For GG genotype carriers, the actionable implication is to reduce the endogenous ligands that activate TLR4 in the vessel wall. Saturated fatty acids — particularly palmitic acid from palm oil, lard, and heavily processed meats — are endogenous TLR4 agonists that trigger vascular inflammation independent of LPS. Substituting with omega-3-rich fats (EPA/DHA) antagonizes TLR4 signaling through FFAR4/GPR120 and reduces downstream NF-κB activation. Periodontal disease is a major source of systemic LPS from Gram-negative oral bacteria; treatment of periodontal inflammation demonstrably reduces systemic inflammatory markers including hsCRP.

Monitoring high-sensitivity CRP (hsCRP) provides a direct readout of the low-grade vascular inflammation that TLR4-pathway variation influences. A value consistently above 2.0 mg/L in a person with a GG genotype and no obvious infection or injury source warrants deeper evaluation for periodontal disease, subclinical infection, and dietary saturated fat load.

Interactions

rs1927911 tags haplotype variation in the TLR4 gene and should be interpreted alongside the coding variants rs4986790 (Asp299Gly) and rs4986791 (Thr399Ile), which directly alter the receptor's extracellular domain and have their own independent evidence for cardiovascular associations. The A20/TNFAIP3 protein (encoded by the TNFAIP3 gene, rs2230926) terminates NF-κB signaling downstream of TLR4; individuals with both high TLR4 inflammatory tone and reduced A20 braking capacity may have amplified vascular inflammatory responses. The NOS2 pathway (rs2779249) is also downstream of NF-κB activation and may compound effects in those with multiple pro-inflammatory genotypes.